LOS ANGELES, March 28, 2012 (GLOBE NEWSWIRE) -- C3 Jian, Inc., a private company focused on providing improved oral healthcare, announced today that Siegfried S. Rogy, Ph.D. has been appointed Senior Director of Clinical Operations, effective immediately.
In this newly made position, Dr. Rogy will report to Vice President of Clinical Operations, Laura A. Navalta, and will be responsible for guiding the Company's clinical programs, including C16G2, a therapeutic peptide targeting dental caries. C3 Jian expects in April 2012 to file an Investigational New Drug application with the U.S. Food and Drug Administration to begin human clinical trials of the C16G2 peptide.
"We are pleased to welcome Dr. Rogy to the team at an exciting time for C3J," said Todd R. Patrick, C3 Jian's President and CEO. "His appointment reaffirms the Company's commitment to advancing dental clinical development and eventually, market access to those drugs that positively affect oral health."
Dr. Rogy brings more than 20 years of clinical development and management in the pharmaceutical industry. He comes to C3 Jian from The Medicines Company where he served as Senior Director of U.S. Clinical Operations. Dr. Rogy's extensive career began at the Austrian-based company Immuo AG and later included positions in clinical project management and development at Baxter Healthcare, Maxim Pharmaceuticals, and Novalar Pharmaceuticals. While at Novalar Dr. Rogy oversaw the management of seven clinical studies that ultimately led to U.S. marketing authorization of OraVerse ®, a therapeutic for the dental market. Dr. Rogy received his Ph.D. in Biology from the Karl-Franzens University in Austria.
"Dr. Rogy has a proven track record in directing quality clinical trials and successfully handling the many challenges that come with them," said Laura A. Navalta, Vice President of Clinical Operations. "His arrival comes at an important time as we plan to start the Company's first Phase 1 clinical trial and continue to advance our product candidates through development."
About C3 Jian, Inc.
C3 Jian is a clinical-stage biotechnology company developing and commercializing novel products to diagnose, treat and prevent diseases related to oral health. C3 is advancing targeted proprietary solutions, which can offer more selective, efficacious and safer treatment modalities for dental applications. The Company's platform cell signaling technology has potential applications beyond oral health and may impact a variety of diseases and disorders particularly related to bacterial and fungal infections. C3 Jian is based in Los Angeles, California. For more information about the company, please visit www.c3-jian.com.
The C3 Jian, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11798